Patents by Inventor Steven Martin Evans

Steven Martin Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-proliferative agents for treating PAH
    Patent number: 11439646
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 13, 2022
    Assignee: Pfizer Inc.
    Inventor: Steven Martin Evans
  • ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH
    Publication number: 20210186974
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 4, 2020
    Publication date: June 24, 2021
    Applicant: Pfizer Inc.
    Inventor: Steven Martin Evans
  • Anti-proliferative agents for treating PAH
    Patent number: 10849903
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 1, 2020
    Assignee: Pfizer Inc.
    Inventor: Steven Martin Evans
  • ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH
    Publication number: 20190240226
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 9, 2017
    Publication date: August 8, 2019
    Applicant: Pfizer Inc.
    Inventor: Steven Martin Evans